Allison Allen
Oregon Health & Science University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Allison Allen.
Jacc-cardiovascular Imaging | 2014
Manish Mehta; Timothy Jacobson; Dawn Peters; Elizabeth Le; Scott M. Chadderdon; Allison Allen; Aaron B. Caughey; Sanjiv Kaul
OBJECTIVES The purpose of this study was to test the hypothesis that handheld ultrasound (HHU) provides a more accurate diagnosis than physical examination in patients with suspected cardiovascular abnormalities and that its use thus reduces additional testing and overall costs. BACKGROUND Despite the limitations of physical examination and the demonstrated superiority of HHU for detecting cardiac abnormalities, it is not routinely used for the bedside diagnosis of cardiac conditions. METHODS Patients referred for a standard echocardiogram for common indications (cardiac function, murmur, stroke, arrhythmias, and miscellaneous) underwent physical examination and HHU by different cardiologists, who filled out a form that also included suggestions for additional testing, if necessary, based on their findings. RESULTS Of 250 patients, 142 had an abnormal finding on standard echocardiogram. Of these, HHU correctly identified 117 patients (82%), and physical examination correctly identified 67 (47%, p < 0.0001). HHU was superior to physical examination (p < 0.0001) for both normal and abnormal cardiac function. It was also superior to physical examination in correctly identifying the presence of substantial valve disease (71% vs. 31%, p = 0.0003) and in identifying miscellaneous findings (47% vs. 3%, p < 0.0001). Of 108 patients without any abnormalities on standard echocardiography, further testing was suggested for 89 (82%) undergoing physical examination versus only 60 (56%) undergoing HHU (p < 0.0001). Cost modeling showed that HHU had an average cost of
Journal of Maternal-fetal & Neonatal Medicine | 2015
Jamie O. Lo; Brian L Shaffer; Allison Allen; Sarah E Little; Yvonne W. Cheng; Aaron B. Caughey
644.43 versus an average cost of
Birth-issues in Perinatal Care | 2015
Ellen L. Tilden; Vanessa R. Lee; Allison Allen; Emily Griffin; Aaron B. Caughey
707.44 for physical examination. This yielded a savings of
American Journal of Obstetrics and Gynecology | 2014
Jamie Krashin; Alison Edelman; Mark D. Nichols; Allison Allen; Aaron B. Caughey; Maria I. Rodriguez
63.01 per patient when HHU was used versus physical examination. CONCLUSIONS When used by cardiologists, HHU provides a more accurate diagnosis than physical examination for the majority of common cardiovascular abnormalities. The finding of no significant abnormality on HHU is also likely to result in less downstream testing and thus potentially reduce the overall cost for patients being evaluated for a cardiovascular diagnosis.
Gynecologic oncology reports | 2017
Allison Allen; Siraj M. Ali; Kyle Gowen; Julia A. Elvin; Tanja Pejovic
Abstract Objective: We examined the morbidities from delivery at earlier gestational ages versus intrauterine fetal demise (IUFD) for women with intrahepatic cholestasis of pregnancy (ICP) to determine the optimal gestational age for delivery. Methods: A decision-analytic model was created to compare delivery at 35 through 38 weeks gestation for different delivery strategies: (1) empiric steroids; (2) steroids if fetal lung maturity (FLM) negative; (3) wait a week and retest if FLM negative; or (4) deliver immediately. Literature review identified 18 studies that estimated IUFD in ICP; we used the mean rate, 1.74%, and assumed a uniform distribution from 34 to 40 weeks gestation. Large cohort data was used to calculate neonatal morbidity rates at each gestational age. Maternal and neonatal quality-adjusted life years (QALYs) were combined. Univariate sensitivity and Monte Carlo analyses were performed to test for robustness. Results: Immediate delivery at 36 weeks without FLM testing and steroid administration was the optimal strategy as compared to delivery at 36 weeks with steroids (+47 QALYs) and as compared to immediate delivery at 35 weeks (+210 QALYs). Our results were robust up to a 30% increase in the rate of IUFD. Conclusion: Immediate delivery at 36 weeks in women with ICP is the optimal delivery strategy.
Journal of Maternal-fetal & Neonatal Medicine | 2015
J. Colin Partridge; Kathryn R. Robertson; Elizabeth E. Rogers; Geri Ottaviano Landman; Allison Allen; Aaron B. Caughey
OBJECTIVE To assess the outcomes and costs of hospital admission during the latent versus active phase of labor. Latent labor hospital admission has been consistently associated with elevated maternal risk for increased interventions, including epidural anesthesia and cesarean delivery, longer hospital stay, and higher utilization of hospital resources. METHODS A cost-effectiveness model was built to simulate a theoretic cohort of 3.2 million term, medically low-risk women either being admitted in latent labor (< 4 cm dilation) or delaying admission until active labor (≥ 4 cm dilation). Outcomes included epidural use, mode of delivery, stillbirth, maternal death, and costs of care. All probability, cost, and utility estimates were derived from the literature, and total quality-adjusted life years were calculated. Sensitivity analyses and a Monte Carlo simulation were used to investigate the robustness of model assumptions. RESULTS Delaying admission until active labor would result in 672,000 fewer epidurals, 67,232 fewer cesarean deliveries, and 9.6 fewer maternal deaths in our theoretic cohort as compared to admission during latent labor. Additionally, delaying admission results in a cost savings of
Journal of Maternal-fetal & Neonatal Medicine | 2018
Allison Allen; Jonathan Snowden; Bernard Lau; Yvonne W. Cheng; Aaron B. Caughey
694 million annually in the United States. Sensitivity analyses indicated the model was robust within a wide range of probabilities and costs. Monte Carlo simulation found that delayed admission was the optimal strategy in 76.79 percent of trials. CONCLUSION Delaying admission until active labor is a dominant strategy, resulting in both better outcomes and lower costs. Issues related to clinical translation of these findings are explored.
Obstetrics & Gynecology | 2014
Bethany Sabol; Shireen de Sam Lazaro; Jennifer Salati; Allison Allen; Jonathan Snowden; Aaron B. Caughey
OBJECTIVE Oregon and federal laws prohibit giving informed consent for permanent contraception when presenting for an abortion. The primary objective of this study was to estimate the number of unintended pregnancies associated with this barrier to obtaining concurrent tubal occlusion and abortion, compared with the current policy, which limits women to obtaining interval tubal occlusion after abortion. The secondary objectives were to compare the financial costs, quality-adjusted life years, and the cost-effectiveness of these policies. STUDY DESIGN We designed a decision-analytic model examining a theoretical population of women who requested tubal occlusion at time of abortion. Model inputs came from the literature. We examined the primary and secondary outcomes stratified by maternal age (>30 and <30 years). A Markov model incorporated the possibility of multiple pregnancies. Sensitivity analyses were performed on all variables and a Monte Carlo simulation was conducted. RESULTS For every 1000 women age <30 years in Oregon who did not receive requested tubal occlusion at the time of abortion, over 5 years there would be 1274 additional unintended pregnancies and an additional
BMJ Sexual & Reproductive Health | 2018
Brian T. Nguyen; Allison Allen
4,152,373 in direct medical costs. Allowing women to receive tubal occlusion at time of abortion was the dominant strategy. It resulted in both lower costs and greater quality-adjusted life years compared to allowing only interval tubal occlusion after abortion. CONCLUSION Prohibiting tubal occlusion at time of abortion resulted in an increased incidence of unintended pregnancy and increased public costs.
Obstetrics and Gynecology Clinics of North America | 2017
Allison Allen; Aaron B. Caughey
Highlights • Genomic alterations may improve diagnostic certainty and subsequent treatment of endometrial stromal sarcoma.• Novel JAZF1-BCORL1 mutation was identified.• Targeted therapeutics to down-stream targets may improve survival benefit in these patients.